FrancophonIA/ELRC3.0 huggingface dataset:
English: Tractocile is given into a vein in three stages, over a maximum of 48 hours: an initial injection into a vein (6.75 mg), followed by a high-dose infusion (18 mg per hour) over three hours, then a lower dose infusion (6 mg per hour) lasting up to 45 hours.
Slovenian: Zdravilo Tractocile se injicira v veno v treh zaporednih korakih v razponu največ 48 ur: najprej injekcija v veno (6,75 mg), ki ji sledi visokoodmerna triurna infuzija (18 mg na uro), in nato infuzija z manjšim odmerkom (6 mg na uro), ki traja do 45 ur.
English: There were too few women with a pregnancy at less than 28 weeks for the effectiveness of Tractocile in comparison to beta-agonists to be established in this group.
Slovenian: V študije je bilo vključenih premalo žensk, nosečih manj kot 28 tednov, da bi bilo mogoče ovrednotiti učinkovitost zdravila Tractocile v primerjavi z beta-agonisti pri tej skupini.
English: Tractocile was compared with ritodine, terbutaline and salbutamol (all from a different class of medicines used in pre-term labour called beta-agonists).
Slovenian: Zdravilo Tractocile so primerjali z ritodinom, terbutalinom in salbutamolom (vsi trije spadajo v drugo skupino zdravil, ki se uporablja pri prezgodnjem porajanju, imenovano beta-agonisti).
English: It must not be used in women whose pregnancy is less than 24 weeks or more than 33 weeks, in women who have premature rupture of the membranes (when the waters break early) after 30 weeks of pregnancy, bleeding from the womb, eclampsia (a dangerous condition at the end of pregnancy caused by toxins in the blood), pre-eclampsia (a condition that can lead to eclampsia) or problems with the baby or placenta, or when continuing the pregnancy could be dangerous for the mother or baby.
Slovenian: Ne sme se uporabljati pri ženskah, ki so noseče manj kot 24 tednov ali več kot 33 tednov ali pri katerih pride do prezgodnjega razpoka plodnega mehurja (kadar voda prezgodaj odteče) po 30 tednu nosečnosti, v primeru krvavitve iz maternice, eklampsije (nevarnega stanja ob koncu nosečnosti, ki ga povzročijo toksini v krvi) ali preeklampsije (stanja, ki lahko povzroči eklampsijo), v primeru težav s plodom ali posteljico oziroma kadar bi bilo nadaljevanje nosečnosti nevarno za mater ali dojenčka.
English: What benefit has Tractocile shown during the studies?
Slovenian: Kakšne koristi je zdravilo Tractocile izkazalo med študijami?
English: By blocking the action of oxytocin, Tractocile prevents contractions and causes the womb to relax, helping to delay birth.
Slovenian: Z zaviranjem delovanja oksitocina zdravilo Tractocile prepreči kontrakcije in povzroči, da se maternica sprosti, kar pomaga k odložitvi poroda.
English: The most common side effect with Tractocile (seen in more than 1 patient in 10) is nausea (feeling sick).
Slovenian: Najpogostejši neželeni učinek zdravila Tractocile (opažen pri več kot 1 bolnici od 10) je navzeja (slabost).
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that Tractocile has shown an effectiveness in delaying pre-term birth that is the same as seen with beta-agonists, and that the better outcome with Tractocile was due to the medicine being better tolerated.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da je zdravilo Tractocile izkazalo enako učinkovitost pri preprečevanju prezgodnjega poroda, kot je bila ugotovljena pri beta-agonistih, ter da je do boljših rezultatov pri uporabi zdravila Tractocile prišlo zaradi boljšega prenašanja tega zdravila.
English: Treatment with Tractocile should be carried out by a doctor who has experience in the treatment of pre-term labour.
Slovenian: Zdravljenje z zdravilom Tractocile mora izvajati zdravnik z izkušnjami s prezgodnjim porajanjem.
English: This means that atosiban blocks the action of oxytocin.
Slovenian: To pomeni, da atosiban zavira delovanje oksitocina.
English: The full EPAR for Tractocile is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tractocile je na voljo tukaj.
English: • dilation of the cervix (the neck of the womb) of 1 to 3 cm and an effacement (a measure of the thinness of the cervix) of 50% or more.
Slovenian: • odprtje materničnega vratu od 1 do 3 cm in stanjšanje za 50 % ali več.
English: What is the risk associated with Tractocile?
Slovenian: Kakšna tveganja so povezana z zdravilom Tractocile?
English: The better result with Tractocile over the beta-agonists might have been because it caused fewer side effects, thereby allowing the patients to receive a full course of treatment.
Slovenian: Zdravilo Tractocile je v primerjavi z beta-agonisti boljše rezultate morda izkazalo zato, ker povzroča manj neželenih učinkov, zaradi česar so bolnice lahko prejele celoten cikel zdravljenja.
English: The ability of Tractocile to delay pre-term birth was studied in 742 women who were 23 to 33 weeks pregnant in three main studies.
Slovenian: Učinkovitost zdravila Tractocile kot terapije za preprečevanje prezgodnjega poroda so proučevali v treh glavnih študijah pri 742 ženskah, ki so bile noseče 23 do 33 tednov.
English: For the full list of all side effects reported with Tractocile, see the Package Leaflet.
Slovenian: Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Tractocile, glejte navodilo za uporabo.
English: Tractocile is a solution for injection, and a concentrate that is made up into a solution for infusion (drip into a vein).
Slovenian: Zdravilo Tractocile je raztopina za injiciranje in koncentrat za pripravo raztopine za infundiranje (kapalno infuzijo v veno).
English: Tractocile is used to delay birth in adult women who are 24 to 33 weeks pregnant, when they show signs that they may give birth pre-term (prematurely).
Slovenian: Zdravilo Tractocile se uporablja za odložitev poroda pri odraslih ženskah, ki so noseče 24 do 33 tednov, če izkazujejo znake, da bi utegnilo priti do prezgodnjega nastopa poroda.
English: Why has Tractocile been approved?
Slovenian: Zakaj je bilo zdravilo Tractocile odobreno?
English: Oxytocin is the hormone involved in starting contractions of the womb.
Slovenian: Oksitocin je hormon, ki sodeluje pri sprožitvi krčenja maternice.
English: How has Tractocile been studied?
Slovenian: Kako je bilo zdravilo Tractocile raziskano?
English: What is Tractocile used for?
Slovenian: Za kaj se zdravilo Tractocile uporablja?
English: How does Tractocile work?
Slovenian: Kako zdravilo Tractocile deluje?
English: What is Tractocile?
Slovenian: Kaj je zdravilo Tractocile?
English: How is Tractocile used?
Slovenian: Kako se zdravilo Tractocile uporablja?
English: Further information on Prasugrel Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije za zdravilo Prasugrel Mylan so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The company also carried out studies that showed that it is ‘bioequivalent' to the reference medicine.
Slovenian: Podjetje je izvedlo tudi študije, ki so pokazale, da je zdravilo „bioekvivalentno“ referenčnemu zdravilu.
English: The materials will include information on how to prescribe the medicine safely and remind doctors that the medicine is not recommended for patients over the age of 75 years.
Slovenian: To bo vključevalo informacije o varnem predpisovanju zdravila in opozorilo zdravnikom, da uporaba zdravila pri bolnikih, starejših od 75 let, ni priporočena.
English: It includes unstable angina (a severe type of chest pain) and heart attack.
Slovenian: Vključuje nestabilno angino pektoris (hudo obliko bolečine v prsih) in srčni infarkt.
English: This means that it helps to prevent blood clots from forming.
Slovenian: To pomeni, da pomaga preprečevati nastajanje krvnih strdkov.
English: What measures are being taken to ensure the safe and effective use of Prasugrel Mylan?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Prasugrel Mylan?
English: The use of Prasugrel Mylan is not recommended in patients over 75 years of age, unless the doctor has carefully considered its benefits and risks, and regards treatment with Prasugrel Mylan as necessary.
Slovenian: Uporaba zdravila Prasugrel Mylan ni priporočena pri bolnikih, starejših od 75 let, razen če zdravnik skrbno prouči njegove koristi in tveganja in oceni, da je zdravljenje z zdravilom Prasugrel Mylan potrebno.
English: Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Efient, and do not need to be repeated for Prasugrel Mylan.
Slovenian: Študije o koristih in tveganjih učinkovine pri odobrenem načinu uporabe so že bile izvedene z referenčnim zdravilom Efient, zato jih ni treba ponoviti za zdravilo Prasugrel Mylan.
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent a heart attack or a stroke.
Slovenian: To preprečuje, da bi trombociti postali „lepljivi“, kar zmanjša tveganje za nastanek krvnega strdka in prispeva k preprečevanju srčnega infarkta ali kapi.
English: Prasugrel Mylan is taken together with aspirin to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in patients with acute coronary syndrome who are undergoing percutaneous coronary intervention.
Slovenian: Zdravilo Prasugrel Mylan se jemlje sočasno z acetilsalicilno kislino (npr. aspirinom) za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročijo krvni strdki in zatrditev arterij) pri bolnikih z akutnim koronarnim sindromom, ki so imeli perkutano koronarno intervencijo.
English: It is recommended that treatment with Prasugrel Mylan and aspirin continue for up to a year.
Slovenian: Priporoča se, da se zdravljenje z zdravilom Prasugrel Mylan in acetilsalicilno kislino nadaljuje do enega leta.
English: In this case, the patient should take 5 mg daily following a 60-mg starting dose.
Slovenian: V tem primeru mora bolnik po začetnem 60-miligramskem odmerku jemati 5-miligramski dnevni odmerek.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Prasugrel Mylan have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Prasugrel Mylan upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Because Prasugrel Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Prasugrel Mylan generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Prasugrel Mylan has been shown to have comparable quality and to be bioequivalent to Efient.
Slovenian: Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Prasugrel Mylan primerljivo raven kakovosti in je bioekvivalentno referenčnemu zdravilu Efient.
English: Acute coronary syndrome is a group of conditions in which blood supply in the vessels supplying the heart is interrupted so heart tissue cannot work properly or dies.
Slovenian: Akutni koronarni sindrom je skupina obolenj, pri katerih je dotok krvi v žilah, ki oskrbujejo srce, prekinjen, zaradi česar srčno tkivo ne more pravilno delovati ali odmre.
English: Prasugrel Mylan is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Slovenian: Zdravilo Prasugrel Mylan je na voljo v obliki tablet (5 in 10 mg), njegovo predpisovanje in izdaja pa je le na recept.
English: Why is Prasugrel Mylan authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Prasugrel Mylan odobreno v EU?
English: Prasugrel Mylan treatment starts with one 60-mg dose.
Slovenian: Zdravljenje z zdravilom Prasugrel Mylan se začne z enim 60-miligramskim odmerkom.
English: The company that markets Prasugrel Mylan will make sure that educational materials are available for doctors who will treat patients with the medicine.
Slovenian: Podjetje, ki trži zdravilo Prasugrel Mylan, bo poskrbelo, da bo zdravnikom, ki bodo bolnike zdravili s tem zdravilom, na voljo izobraževalno gradivo.
English: As for every medicine, the company provided studies on the quality of Prasugrel Mylan.
Slovenian: Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Prasugrel Mylan.
English: For more information about using Prasugrel Mylan, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Prasugrel Mylan glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: This means that Prasugrel Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Efient.
Slovenian: To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Efient.
English: This is then followed by 10 mg taken once a day, except in patients weighing less than 60 kg, who should take 5 mg once a day.
Slovenian: Temu sledi 10-miligramski odmerek enkrat na dan, razen pri bolnikih, ki tehtajo manj kot 60 kg, ki morajo vzeti 5 mg enkrat na dan. Bolniki, ki jemljejo zdravilo Prasugrel Mylan, morajo prav tako jemati acetilsalicilno kislino, in sicer v odmerku, ki jim ga je predpisal zdravnik.
English: What is Prasugrel Mylan and what is it used for?
Slovenian: Kaj je zdravilo Prasugrel Mylan in za kaj se uporablja?
English: As for all medicines, data on the use of Prasugrel Mylan are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Prasugrel Mylan stalno spremljajo.
English: Percutaneous coronary intervention is a procedure used to unblock the blood vessels supplying the heart.
Slovenian: Perkutana koronarna intervencija je postopek za odpravo zapor krvnih žil, ki oskrbujejo srce.
English: Side effects reported with Prasugrel Mylan are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Prasugrel Mylan, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: An overview of Prasugrel Mylan and why it is authorised in the EU
Slovenian: Pregled zdravila Prasugrel Mylan in zakaj je odobreno v EU
English: What are the benefits and risks of Prasugrel Mylan?
Slovenian: Kakšne so koristi in tveganja zdravila Prasugrel Mylan?
English: Prasugrel Mylan contains the active substance prasugrel and is a ‘generic medicine'.
Slovenian: Zdravilo Prasugrel Mylan vsebuje učinkovino prasugrel in je „generično zdravilo“.
English: Therefore, the Agency's view was that, as for Efient, the benefit of Prasugrel Mylan outweighs the identified risk and it can be authorised for use in the EU.
Slovenian: Zato je agencija menila, da koristi zdravila Prasugrel Mylan, enako kot pri zdravilu Efient, odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
English: Blood clots are caused by special cells in the blood, the platelets, sticking together (aggregating).
Slovenian: Krvne strdke povzroča zlepljanje (agregacija) posebnih celic v krvi, imenovanih trombociti.
English: Other information about Prasugrel Mylan
Slovenian: Druge informacije o zdravilu Prasugrel Mylan
English: Prasugrel stops the platelets aggregating by blocking a substance called ADP from binding to a receptor (target) on their surface.
Slovenian: Prasugrel z zaviranjem vezave snovi, imenovane ADP (adenozin difosfat), na receptor (prijemališče) na površini trombocitov prepreči njihovo agregacijo.
English: How is Prasugrel Mylan used?
Slovenian: Kako se zdravilo Prasugrel Mylan uporablja?
English: How does Prasugrel Mylan work?
Slovenian: Kako zdravilo Prasugrel Mylan deluje?
English: The active substance in Prasugrel Mylan, prasugrel, is an inhibitor of platelet aggregation.
Slovenian: Učinkovina v zdravilu Prasugrel Mylan, prasugrel, je zaviralec agregacije trombocitov.
English: Prasugrel Mylan received a marketing authorisation valid throughout the EU on 16 May 2018.
Slovenian: Prasugrel Mylan (prasugrel) EMA/203583/2018
English: How has Prasugrel Mylan been studied?
Slovenian: Kako je bilo zdravilo Prasugrel Mylan raziskano?
English: Pack size
Slovenian: Subkutana uporaba e
English: Article 29(4) of Directive 2001/83/EC, as amended.
Slovenian: Člen 29(4) Direktive 2001/83/ES, kakor je bila spremenjena.
English: The Reference Member State was Hungary and the Concerned Member States were Czech Republic, Estonia, Hungary, Lithuania, Latvia, Poland, Romania and Slovak Republic.
Slovenian: Referenčna država članica je bila Madžarska, zadevne države članice pa Češka republika, Estonija, Madžarska, Litva, Latvija, Poljska, Romunija in Slovaška.
English: The Mutual Recognition Procedure started on 3 August 2007.
Slovenian: Postopek medsebojnega priznavanja se je začel dne 3. avgusta 2007.
English: The final opinion was converted into a Decision by the European Commission on 12 November 2008.
Slovenian: Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 12. novembra 2008.
English: The Czech Republic and Latvia referred the reasons for disagreement to the EMEA on 1 February 2008.
Slovenian: Češka republika in Latvija sta svoje razloge za nesoglasje agenciji EMEA podali dne 1. februarja 2008.
English: The arbitration procedure started on 21 February 2008 with the adoption of a list of questions.
Slovenian: Arbitražni postopek se je začel 21. februarja 2008 s sprejetjem seznama vprašanj.
English: Concerns related to the formal proof of bioequivalence and the lack of a wide therapeutic experience which were considered a potential serious risk to public health.
Slovenian: Zadržki so se nanašali na uradni dokaz biološke enakovrednosti in pomanjkanje obsežnih terapevtskih izkušenj, kar se je štelo kot možno resno tveganje za javno zdravje.
English: These Member States were not able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Slovenian: Te države članice niso mogle doseči soglasja glede medsebojnega priznavanja dovoljenja za promet z zdravilom, ki ga je odobrila referenčna država članica.
English: The Rapporteur was Dr Ondřej Slanař (CZ) and Co-Rapporteur(s) was Prof János Borvendég (HU).
Slovenian: Poročevalec je bil dr. Ondřej Slanař (CZ), soporočevalec pa prof. János Borvendég (HU).
English: The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Slovenian: Seznam zadevnih imen izdelkov je naveden v Dodatku I. Znanstveni zaključki so navedeni v Dodatku II, povzetek glavnih značilnosti zdravila pa v Dodatku III.
English: The Summary of Product Characteristics, Labelling and Package Leaflet of the Reference Member State should be amended.
Slovenian: Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo referenčne države članice je treba spremeniti.
English: During their July 2008 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lisonorm, that the objections raised by Czech Republic and Latvia should not prevent the granting of a Marketing Authorisation.
Slovenian: CHMP je na zasedanju julija 2008 ob upoštevanju vseh predloženih podatkov in znanstvene razprave v okviru Odbora menil, da je razmerje med koristnimi učinki in tveganji za zdravilom Lisonorm ugodno, da zadržki, ki sta jih podali Češka republika in Latvija, ne bi smeli preprečiti odobritve dovoljenja za promet z zdravilom.
English: Lisonorm tablet contains 5mg amlodipine/ 10mg lisinopril and is an anti-hypertensive indicated in patients with blood pressure adequately controlled with lisinopril and amlodipine given concurrently at the same dose level.
Slovenian: Tableta Lisonorm vsebuje 5 mg amlodipina /10 mg lizinoprila in je antihipertenziv, indiciran za bolnike, pri katerih je krvni tlak primerno nadzorovan z lizinoprilom in amlodipinom, ki se bolniku dajeta sočasno pri enakem odmerku zdravila.
English: A positive opinion was adopted by consensus on 24 July 2008.
Slovenian: Odbor je dne 24. julija 2008 na podlagi soglasja izdal pozitivno mnenje.
English: The Marketing Authorisation Holder provided written explanations on 2 June 2008.
Slovenian: Imetnik dovoljenja za promet z zdravilom je predložil pisna pojasnila 2. junija 2008.
English: Gedeon Richter Plc obtained a national marketing authorisation for Lisonorm which was authorised in Bulgaria on 29 December 2006, before Bulgaria joined the European Union.
Slovenian: Družba Gedeon Richter Plc je prejela nacionalno dovoljenje za promet z zdravilom Lisonorm, ki je bilo odobreno v Bolgariji dne 29. decembra 2006, preden se je Bolgarija pridružila Evropski uniji.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Lisonorm and associated names International Non-Proprietary Name (INN): lisinopril + amlodipine
Slovenian: ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 29(4)1 ZA ZDRAVILO Lisonorm in z njim povezana imena Mednarodno nelastniško ime (INN): lizinopril + amlodipin
English: Gedeon Richter Plc submitted a Marketing Authorisation Application (MAA) via mutual recognition procedure for Lisonorm on the basis of the marketing authorisation granted by Hungary on 30 April 2004.
Slovenian: Družba Gedeon Richter Plc je predložila vlogo za odobritev dovoljenja za promet s postopkom medsebojnega priznavanja za zdravilo Lisonorm, in sicer na podlagi dovoljenja za promet z zdravilom, ki ga je odobrila Madžarska dne 30. aprila 2004.
English: 27 July 2010
Slovenian: 27. julija 2010
English: The final opinion was converted into a Decision by the European Commission on 27 July 2010.
Slovenian: Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 27. julija 2010.
English: 1 Article 34 of Directive 2001/82/EC
Slovenian: 1 Člen 34 Direktive 2001/82/ES
English: The referral procedure started on 15 October 2008.
Slovenian: Napotitveni postopek se je začel 15. oktobra 2008.
English: Oral explanations were given on 10 February 2010.
Slovenian: Ustna pojasnila so bila podana dne 10. februarja 2010.
English: The target species are: pigs, chickens, turkeys and rabbits.
Slovenian: Ciljne vrste so: prašiči, piščanci, purani in zajci.
English: Opinion following an Article 34
Slovenian: Mnenje v zvezi z napotitvijo v skladu s členom 34
English: Written explanations were provided by the marketing authorisation holders on 20 April 2009 and 16 November 2009.
Slovenian: Pisna pojasnila so imetniki dovoljenja za promet z zdravilom predložil dne 20. aprila 2009 in 16. novembra 2009.
English: The rapporteur and co-rapporteur appointed were: Prof. Stane Srčič and Dr Karolina Törneke respectively.
Slovenian: Za poročevalca oziroma soporočevalko sta bila imenovana: prof. Stane Srčič in dr. Karolina Törneke.
English: Tiamulin is a semi-synthetic antibiotic belonging to the pleuromutilin group of antibiotics and it is used only in veterinary medicine.
Slovenian: Tiamulin je polsintezni antibiotik iz skupine antibiotikov pleuromutilinov in se uporablja le v veterinarski medicini.
English: referral for Tiamutin premix and associated names
Slovenian: za zdravilo Tiamutin premix in z njim povezana imena